Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies

Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is rapidly metabolized to its active metabolite, eslicarbazepine, which acts primarily by enhancing slow inactivation of vol...

Descripción completa

Detalles Bibliográficos
Autores principales: Shorvon, S. D., Trinka, E., Steinhoff, B. J., Holtkamp, M., Villanueva, V., Peltola, J., Ben-Menachem, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336540/
https://www.ncbi.nlm.nih.gov/pubmed/28101651
http://dx.doi.org/10.1007/s00415-016-8338-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336540/
https://www.ncbi.nlm.nih.gov/pubmed/28101651
http://dx.doi.org/10.1007/s00415-016-8338-2

Ejemplares similares